News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Santarus Inc. (SNTS) Announces Presentation of Phase 3 Data for Rifamycin SV MMX in Travelers’ Diarrhea


10/4/2013 9:55:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS) today announced that new data from its Phase III clinical study with the investigational drug rifamycin SV MMX® in patients with travelers’ diarrhea will be featured in a poster presentation at IDWeek™ in San Francisco at the Moscone Center (Poster Hall C) from 12:30 p.m. to 2:00 p.m. Pacific Time on Saturday, October 5, 2013. The poster (#1306) is titled, Randomized, Double-Blind, Placebo-Controlled Study of Rifamycin SV MMX in the Treatment of Travelers’ Diarrhea. IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   
Diarrhea

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES